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ABSTRACT 
Reports from Asia and other parts of the world have demonstrated that the incidence of Candida auris infection is on the rise. 
Candida auris is a fungal pathogen causing a wide variety of infections affecting people of all age groups. Candida auris was 
first described in 2009 and has since emerged as an important cause of invasive fungal infection, most importantly healthcare-
associated candidaemia. Large outbreaks have been reported worldwide, with therapeutic failure and associated high mortality 
rates recorded. 
The emergence and spread of C. auris raises public health concerns because of some characteristics of this pathogen. First it is 
resistant to many antifungal agents making this infection very difficult to treat. It is also associated with horizontal 
transmission in health care settings causing outbreaks among hospitalized individuals with high mortality rates. Furthermore, 
identification of C auris is a challenge. Routine identification methods usually misidentify the organism as other yeasts 
especially Candida haemulonii. 
This review discusses the current knowledge on the epidemiology, treatment and control of this infection. The urgent need for 
the stakeholders in Nigerian tertiary hospitals to set machinery in motion for prompt diagnosis, management and prevention of 
transmission of this infection are also discussed.  
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Des rapports en provenance d'Asie et d'autres parties du monde ont démontré que l'incidence de l'infection à Candida auris est 
en augmentation. Candida auris est un pathogène fongique causant une grande variété d'infections affectant les personnes de 
tous les groupes d'âge. Candida auris a été décrit pour la première fois en 2009 et est depuis apparu comme une cause 
importante d'infection fongique invasive, surtout la candidémie associée aux soins de santé. De grandes épidémies ont été 
signalées dans le monde entier, avec des échecs thérapeutiques et des taux de mortalité élevés associés enregistrés. 
L'émergence et la propagation de C. auris soulèvent des préoccupations en matière de santé publique en raison de certaines 
caractéristiques de ce pathogène. D'abord, il est résistant à de nombreux agents antifongiques rendant cette infection très 
difficile à traiter. Il est également associé à la transmission horizontale dans les milieux de soins de santé, ce qui provoque des 
éclosions parmi les personnes hospitalisées avec des taux de mortalité élevés. De plus, l'identification de C auris est un défi. Les 
méthodes d'identification de routine confondent généralement l'organisme avec d'autres levures, en particulier Candida 
haemulonii. 
Cette revue discute les connaissances actuelles sur l'épidémiologie, le traitement et le contrôle de cette infection. Le besoin 
urgent pour les parties prenantes des hôpitaux tertiaires du Nigeria de mettre en place un système de diagnostic rapide, de prise 
en charge et de prévention de la transmission de cette infection est également discuté. 
 
INTRODUCTION 
Candidaemia and candidiasis are usually caused by 
Candida albicans but infections due to non albicans 
Candida species have been on the increase globally. (1) 
Cases of invasive non albicans candidiasis have been 
reported from many parts of the world. Among the  
 
non albicans Candida species; C. glabrata and C. 
tropicalis have emerged as important opportunistic 
pathogens with other species being reported to a 
lesser degree. 
Copyright ©2018 AJCEM. This work is licensed under the Creative Commons Attribution 4.0 International License CC-BY 
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In 2009, a novel yeast species belonging to the genus 
Candida was isolated from the external ear canal of a 
patient admitted in a Japanese hospital. (2) DNA 
analysis revealed this new species to be closely 
related Candida ruelliae and Candida haemulonii in the 
Metschnikowiaceae clade. It was thereafter named as 
C. auris based on its first isolation from an ear 
infection. (2)  
Candida auris is an unusual Candida species first found 
in human ear specimens. It is capable of hospital 
acquired transmission leading to large outbreak in 
health care settings. (3) It has emerged as a significant 
pathogen in hospitals and accounts for 8.6% to 30% of 
cases of candidaemia in a recent report. (4)   
Contaminated surfaces was thought to be the source 
of dissemination of  C. auris, however, urogenital 
colonization from an indwelling urinary catheter 
could also result in dissemination to the blood stream 
causing fungemia. (5, 6)  
 
EPIDEMIOLOGY 
Candida auris has become an important nosocomial 
pathogen with widespread dissemination across 
several Asian countries and other parts of the world. 
(7) The actual global picture remains unclear as the 
current commercial methods of laboratory diagnosis 
misidentify C. auris (8)  
Since it was first reported in Japan in 2009, C auris has 
been reported in many other regions of the world. (2) 
In South Korea, it was isolated in fifteen cases of 
chronic otitis media and subsequently in three 
patients with blood stream infections across three 
different hospitals. (9) Candidaemia caused by C. 
auris has also been reported in India and South Africa, 
with an estimated prevalence of 0.3%. (10) (6) The first 
cases in the United Kingdom were recorded in 2013 
from blood cultures, thereafter there have been many 
others documented including outbreaks in 2013 and 
2015-2016. (3, 7)  In the United States, C. auris has 
been identified from over 122 patients, 77 clinical 
cases and 45 patient contacts. Majority of the cases 
were in New York. (11) Whole-genome sequencing of 
C. auris isolates has shown, clustering into four 
distinct clades. (11) Studies have found that isolates 
from within each geographical region are highly 
related to one another whereas isolates from different 
regions did not exhibit such relatedness. (11, 12) 
These suggest independent emergence of C. auris 
within geographical regions followed by local 
transmission. (11, 12) This geographically specific 
clustering of C auris has also been demonstrated in a 
study involving samples from the India, South Africa, 





C. auris has an innate pliability for survival and 
persistence in the hospital environment; it is able to 
rapidly colonize patients’ skin and is highly 
transmissible within the healthcare setting.  (3). This 
has led to serious and protracted outbreaks. C. auris 
does not produce hyphae and produces only 
rudimentary pseudohyphae, however many strains 
are highly pathogenic with some as pathogenic as C 
albicans. (7), (14) Various virulence factors are 
responsible for the ability of  C. auris to easily survive 
and persist in infection sites. Phospholipases are 
extracellular hydrolytic enzymes which help in 
adherence and invasion of host cells and this has been 
demonstrated in C.  auris. (14, 15)   C. auris also 
produces heamolysin leading to invasive disease and 
widespread infection. (15) Proteinase activity has also 
been demonstrated in C. auris and is said to be in 
higher proportion than phospholipase production. 
(15) (14) 
 
Some isolates of C.  auris have been noted to form 
large aggregates as a result of failure of budding yeast 
to separate. This observation was found in cases of 
lethal infection and it is thought that aggregation 
might be a mode of immune evasion and tissue 
persistence. (7) (16) 
Earlier studies had also reported the lack of biofilm 
production by C. auris compared to its counterpart C. 
haemulonii. (17)  Subsequent researches have however 
demonstrated that C. auris is able to differentially 
adhere to polymeric surfaces, form biofilms, and 
resist antifungal agents.  (18) These biofilms are, 
however, much thinner than those formed by C. 
albicans and have a limited amount of extracellular 
matrix. (14) C. auris is also able to grow at high 
temperatures of 37°C–42°C and exhibit lethality and 
tissue invasion close to that of C. albicans, the most 
pathogenic Candida species. (16)  
 
RISK FACTORS 
Individuals at extreme ages have been noted to be at 
high risk of infection. (9) Presence of foreign bodies 
such as central venous catheters, urinary catheters 
and mechanical ventilation also increase the risk of 
infection. (9) (19) (6) Concomitant use of broad-
spectrum antibiotics and use of antifungals puts the 
patient at higher risk. (6, 13)  A case series involving 
many countries has found intensive care stay to be a 
major risk factor for C. auris infections which is 
similar to other studies.  (3, 13, 19) 
Comorbidities and immunosuppressive conditions 
such as diabetes mellitus, chronic kidney disease, 
cancer chemotherapy, hematologic malignancies, and 
bone marrow transplantation have also been 
identified.  (1) (20)   Additional risk factors are 
erythrocyte transfusion, parenteral nutrition, 
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abdominal surgery, hemodialysis, pancreatitis and 
HIV infection. (9) (13) (19) (20)    
Neutropenia does not appear to carry appreciable risk 
according to available reports. (9), (1)    
A study found longer ICU stay, underlying 
respiratory disease, vascular surgery, medical 
intervention and exposure to antifungals as the major 
risk factors for acquiring C. auris infection. (21)    
 
CLINICAL CONDITIONS 
C. auris is an emerging fungal pathogen that can cause 
a wide range of human infections especially in 
intensive care settings (22), (4) The clinical spectrum 
of C. auris infections has expanded from minor cases 
of superficial infections to highly invasive 
bloodstream infections. (8) It is a source of multi-
resistant health-care associated infections with a high 
potential for horizontal transmission in the hospital 
setting. (23) Many studies including that by Schelenz 
et al have demonstrated such transmission in 
hospitalized patients. (3) Candida auris is a recognized 
cause of chronic otitis media, wound infections, 
including diabetic foot. (22) (7).  The occurrence of 
candidaemia due to C auris appears to be on the 
increase and is associated with high mortality of up to 
50%.  (3) (7) (11) C. auris accounted for 30% of the 
annual candidaemia cases in a tertiary care general 
hospital; most of the patients had persistent 
candidaemia with overall mortality rates of 30- 50%. 
(6)  C auris had also been reported as a cause of 
bronchopneumonia. (22), (11) Other sites where C 
auris has been cultured are urine, bile fluid, bone and 
jejunum. (11)  
 
LABORATORY DIAGNOSIS 
Specimens for laboratory diagnosis depend on clinical 
presentation and include blood, sputum, swabs, urine 
and others.  On Sabouraud dextrose agar (SDA), 
colonies of C. auris are white to cream colored and 
smooth. (9), (4) Microscopic examination shows ovoid 
to globose budding yeast cells in singles or pairs. (4)  
C. auris does not form chlamydoconidia or 
pseudohyphae on cornmeal agar. (4) (14)  It failed to 
form Chlamydospores even after 3 days of growth on 
Cornmeal agar at 30°C. (6) It grows well at 37 and up 
to 42°C but does not grow at 45°C. (9) (6) No growth 
has been observed on cycloheximide-containing 
medium. (9) Urease test and nitrate assimilation test 
are both negative in C. auris.  (9)   In contrast to C. 
auris, C. haemulonii and C. duobushaemulonii isolates 
produce pseudohyphae and do not grow at 42°C. (4)  
Assimilation of N-acetylglucosamine (NAG) is quite 
variable and therefore not valid in differentiating C. 
auris from C. pseudohaemulonii. (4) (6) It appears pink 
on CHROM-agar Candida medium and grows at 37°C 
and 42°C. (6)  
 
Although C. auris is close phylogenetically to Candida 
haemulonii and Candida ruelliae in the 
Metschnikowiaceae clade analyses of the 26S rDNA 
D1/D2 domain, nuclear ribosomal DNA ITS region 
sequences, and also chemotaxonomic studies have 
indicated that it represents a new species. The 
taxonomic description of Candida auris sp. nov. was 
proposed in 2009. (2)  
Unfortunately, the usual phenotypic tests are unable 
to correctly identify C auris which is misidentified as 
one of the closely related Candida species especially C 
haemulonii.  
The Vitek 2 system is unable to differentiate between 
isolates of C. auris and those of C. haemulonii and 
Candida pseudohaemulonii identifying them as C. 
haemulonii or C. famata. (9), (6), (10) 
In addition, the API 20C system, identified isolates of 
C. auris as Rhodotorula glutinis, or C. sake while C. 
haemulonii and C. pseudohaemulonii were identified as 
Kodamaea ohmeri.(9) (6) 
Currently, the reliable methods for definitive 
identification of C. auris are molecular based methods 
such as PCR, sequencing analysis, amplified fragment 
length polymorphism (AFLP) fingerprinting and 
MALDI-TOF biotyping. (1, 3, 13) Internal transcribed 
spacer  (ITS) region  sequencing is used to confirm the 
identity of suspected isolates as C. auris. (6), (1),  (3), 
(4)  
 
Matrix assisted laser desorption ionization–time of 
flight mass spectrometry (MALDI-TOF MS) can be 
used to identify related species of Candida. (4) AFLP 
has been shown to reliably distinguish C. auris from 
other closely related species such as C. haemulonii, C. 
pseudohaemulonii and C. duobushaemulonii. (3) In 
addition, REAG-N can be used for epidemiologic 
typing of C. pseudohaemulonii and C. auris isolates. (17)   
A cheap method was devised by Kumar et al for 
identifying C. auris among isolates identified by 
VITEK2 as members of C. haemulonii complex. 
CHROMagar Candida medium is supplemented with 
Pal's agar and on this medium C. auris strains show 
confluent growth of white to cream colored smooth 
colonies both at 37°C and 42°C without 
pseudohyphae production. On the contrary, C. 
haemulonii complex isolates show poor growth of 
smooth, light-pink colonies later becoming semi-
confluent with pseudohyphae production. (24) 
 
ANTIFUNGAL RESISTANCE  
C. auris has a phylogenetic relationship with Candida 
krusei, C. haemulonii, and C. lusitaniae. These species 
are known to have either intrinsic or inducible 
resistance to antifungal agents such as fluconazole 
and amphotericin B. (12) There are at present no 
epidemiological cutoff values (ECVs) or clinical 
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breakpoints defined for C. auris, thus non species-
specific breakpoints are usually used. (25)  
C. auris isolates are resistant to fluconazole with high 
MICs observed in virtually all reports. (6), (1) (10)  (4) 
Among the other azoles, isavuconazole, 
posaconazole, itraconazole and voriconazole, potent 
activity against C. auris has been demonstrated. 
(1),(26) The results are however inconsistent as 
variable results have been observed depending on the 
study. One study found posaconazole to have the 
most potent activity in vitro followed by 
isavuconazole then itraconazole. (25) Reduced 
susceptibility voriconazole has been demonstrated in 
some isolates but with excellent activity of 
isavuconazole and posaconzole. (10), (4)  In contrast, 
another study observed resistance to itraconazole but 
susceptibility to voriconazole. (15) Flucytosine also 
shows excellent in vitro activity. (6) 
In most investigations, Amphotericin B showed 
excellent activity against C auris athough a few cases 
of resistance have been observed. (1), (6),  (10), (15), 
(25) 
The echinocandins, caspofungin, anidulafungin and 
micafungin, have excellent activity against the 
organism.(1, 6, 10)   C. auris resistant to all classes of 
antifungals including echinocandin has been 
reported, thereby emphasizing the importance of 
antifungal susceptibility testing. (13)  
In summary, C auris exhibits uniform resistance to 
fluconazole, variable susceptibility to the other azole 
antifungals and a low acquired resistance to 
amphotericin B and the echinocandins. (25)  
 
ANTIFUNGAL THERAPY  
The first-line therapy is an echinocandin, pending the 
results of susceptibility testing, which should be 
carried out without delay. (27)  Duration of antifungal 
therapy is like other infections caused by other 
Candida spp. In candidaemia, treatment should be 
continued for 14 days after resolution of symptoms 
attributable to candidaemia and also documented 
evidence of clearance of Candida from the 
bloodstream. (27)  A novel drug, SCY-078, the first 
orally bioavailable 1, 3-β-D-glucan synthesis inhibitor, 
has demonstrated potent antifungal activity against 
various Candida spp including C. auris. (14) 
 
INFECTION PREVENTION AND CONTROL 
Similar to other Candida infections, C. auris infections 
appear to be hospital acquired, occurring several days 
to weeks into a patient’s hospital stay. (12, 27) This 
suggests an exogenous rather than endogenous 
source of infection and a breach of infection control 
procedures. In cases of infections, environmental 
sampling has showed persistent presence of C. auris 
around bed space areas. (3) Implementation of strict 
infection control is therefore of paramount 
importance in the control of this infection. (11) 
Cases and their contacts should be cohorted / 
isolated; and patient housed in a private room. Before 
de-isolating the patient, a series of three negative 
screens taken 24 hours apart is advocated. (27)  To 
decrease the risk for transmission, health care 
personnel in acute care settings should use Standard 
and Contact Precautions. Personal protective clothing 
including cuffed long-sleeved disposable gowns, 
gloves and aprons should be worn by health care 
workers. (3) Decolonization of C. auris infected 
patients can be performed using chlorhexidine 
formulations depending on the site. Oral nystatin can 
also be prescribed if oropharyngeal colonization is 
present. (3)  Environmental decontamination can be 
implemented using chlorine-based products and 
hydrogen peroxide vapour. (3)   
 
When transferring colonized patients to other health 
care facilities, the receiving facilities need to be 
notified of the presence of this multidrug-resistant 
organism so as to ensure that appropriate precautions 
are adhered to. There should be thorough daily and, 
also on discharge of patient, terminal cleaning of 
rooms of patients infected with C. auris infections, 
using a disinfectant active against Clostridium difficile 
spores. (11, 20) Equipment used for patients should be 
cleaned and disinfected with hydrogen peroxide 
vapour. (3)  Screening for C. auris in units having 
patients with ongoing infections or patients coming 
from other affected hospitals/units or patients at risk 
for candidiasis may be conducted. Suggested 
screening sites are: Nose, throat, and groin, 
urine/urethral swab, perineal or low vaginal swab, 
sputum/endotracheal secretions, wounds and other 
appropriate sites. All screen-positive patients should 
be isolated or cohorted. (27)  
 
PROGNOSIS 
Candida auris is an emerging healthcare-associated 
fungal pathogen associated with high mortality rate 
of 40-70%.  (12) (1) Patients may have therapeutic 
failure with persistent candidaemia in spite of 
antifungal treatment which results in fatal outcomes. 
(6, 9, 20)  
Recurrent C. auris candidaemia occurring 3 to 4 
months after the initial episode of infection is another 
complication that may be encountered C. auris. (20)   
Overall outcome is usually better when infection 
prevention measures are in place. (18) 
 
LEVEL OF PREPAREDNESS IN NIGERIA AND 
FUTURE DIRECTIVE  
Nosocomial outbreaks as well as recovery of 
laboratory confirmed isolates of C. auris have not been 
reported in Nigeria. More assertive infection control 
measures and steps should be put in place to prevent 
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the transmission of the organism in our health care 
settings. Candida auris infection should be suspected 
when the isolate is recovered from the critically ill 
patients in different Intensive Care units (ICU) in our 
tertiary hospitals. According to the recommendation 
of Centre for Disease control (CDC), all Candida 
isolates recovered from sterile sites should be 
identified to the species level so that initial empirical 
treatment can be administered on species -specific 
antifungal susceptibility patterns(28, 29). All 
healthcare facilities in Nigeria with high clinical 
suspicion of inpatients with C. auris should contact 
the local authority as well as the Federal Ministry of 
Health (FMoH) for notification.  
 
Medical laboratories should emphasise the 
importance of accurate species identification for 
Candida to a species level. Many Medical 
Microbiology laboratories do not routinely speciate 
non-Candida albicans isolates or utilize yeast 
identification methods such as chromogenic agar, 
biochemical tests (API) or automated systems such as 
VITEK which do not speciate this pathogen or may 
misidentify C. auris as yeasts such as Candida 
haemulonii, Candida sake, and Rhodotorula 
mucilaginosa.(30) Clinical laboratories should be 
encouraged to forward C. haemulonii isolates and 
isolates not identified beyond Candida spp. by 
conventional methods to tertiary or public health 
laboratories in Nigeria for further characterization. 
Antifungal resistance is an important concern in 
managing invasive Candida infections, Therefore, 
understanding drug susceptibility of these different 
species can help develop protocols for appropriate 
empirical treatment of these infections. We 
recommend that each hospital should put in place 
good antimicrobial stewardship programme and 
monitor the antifungal susceptibility pattern against 
this organism. In addition, each hospital should 
develop their guidelines and policies for the control 
and prevention of C. auris infection. 
. 
CONCLUSION 
There should be high level of clinical suspicions when 
non-albicans Candida are isolated in high risk patients 
admitted in intensive care units. Antifungal 
susceptibility testing should be initiated and 
performed routinely in all our tertiary hospitals and 
public medical microbiology laboratories. If there 
should be any report of positive cases, infected 
patients should be cared for in an isolated single room 
to prevent transmission of the pathogen.  
Other aggressive infection control measures should 
be implemented in the hospitals. These include 
stringent hand hygiene procedures before and after 
touching the patients and items around the bed sides; 
cleaning of affected clinical areas with high strength 
chlorine-based agents and prompt treatment of 
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